People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

"That's a big one," said Trump, as he was handed the WHO order to sign among dozens of others, in a signal of his ...

In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication ...

While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

In Part 4 of our Life Sciences Industry Report, we turn our attention to advanced data analytics, wearable health devices, ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...